Shelia M. Violette, Ph.D., is the CSO of Admirix and has been an Entrepreneur in Residence at Atlas Venture since 2017. Dr. Violette served as Vice President of Tissue Injury and Fibrosis at Biogen-Idec., where she spearheaded a team of scientists conducting discovery research and developing translational approaches to advance programs into clinical development. Dr. Violette has more than 20 years of experience in drug development, advancing programs from early stage research to clinical development. This has included studying the role of the alphavbeta6 integrin in many forms of tissue injury and fibrosis and developing a humanized monoclonal antibody that is in clinical development. Prior to Biogen-Idec, she served as Vice President of Research at Stromedix, Inc. from 2008 to 2012 and led all research activities supporting the development of the anti-v6 antibody, STX-100. She has been Member of Scientific Advisory Board at Scholar Rock, Inc. since May 25, 2017. She served as Director in Immunology at Biogen Idec and previously the Research Head for the Fibrosis. She also worked at ARIAD Pharmaceuticals and Repligen. Dr. Violette serves as a Member of Scientific Advisory Board at Morphic Rock Therapeutic, Inc. She has provided strategic and operational leadership to multi-disciplinary teams of scientists and authored more than 80 manuscripts and patents. Dr. Violette has directed research and led therapeutic programs at several biotechnology companies including Repligen, Ariad, Stromedix and Biogen.She has a BS from Massachusetts College of Pharmacy in 1983 and a PhD in pharmacology from Yale University in 1989. She carried out her post-doctoral training with Frank Ruddle in the Department of Biology at Yale University.
Christopher Garbe, MS MBA
Director of Quality Charles C. Gates Biomanufacturing Facility